Public health impact and return on investment of the pediatric immunization program in Poland

BACKGROUNDThis study aims to evaluate the epidemiological impact and return on investment of the pediatric immunization program (PIP) in Poland from the healthcare-sector and societal perspectives.RESEARCH DESIGN AND METHODSA health-economic model was developed focusing on the nine vaccines, targeti...

Full description

Saved in:

Bibliographic Details
Published in:	Expert review of vaccines Vol. 22; no. 1; pp. 1114 - 1125
Main Authors:	Mellott, Claire E., Jaworski, Rafal, Carrico, Justin, Talbird, Sandra E., Dobrowolska, Iwona, Golicki, Dominik, Bencina, Goran, Clinkscales, Micah, Karamousouli, Eugenia, Eiden, Amanda L, Sabale, Ugne
Format:	Journal Article
Language:	English
Published:	Taylor & Francis Group 31-12-2023
Subjects:	benefit–cost ratio pediatric return on investment Vaccination
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	BACKGROUNDThis study aims to evaluate the epidemiological impact and return on investment of the pediatric immunization program (PIP) in Poland from the healthcare-sector and societal perspectives.RESEARCH DESIGN AND METHODSA health-economic model was developed focusing on the nine vaccines, targeting 11 pathogens, recommended by the public health authorities for children aged 0-6 years in Poland. The 2019 birth cohort (388,178) was followed over their lifetime, with the model estimating discounted health outcomes, life-years gained, quality-adjusted life-years, and direct and indirect costs with and without the PIP based on current and pre-vaccine - era disease incidence estimates, respectively.RESULTSAcross 11 targeted pathogens, the Polish PIP prevented more than 452,300 cases of disease, 1,600 deaths, 37,900 life-years lost, and 38,800 quality-adjusted life-years lost. The PIP was associated with vaccination costs of €54 million. Pediatric immunization averted €65 million from a healthcare-sector perspective (benefit-cost ratio [BCR], 2.2) and averted €358 million from a societal perspective (BCR, 7.6). The BCRs from both perspectives remained >1.0 in scenario analyses.CONCLUSIONSThe Polish PIP, which has not previously been systematically assessed, brings large-scale prevention of disease-related morbidity, premature mortality, and associated costs. This analysis highlights the value of continued investment in pediatric immunization in Poland.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1476-0584 1744-8395
DOI:	10.1080/14760584.2023.2275712